Biblio Discovery — Demo Discovery Service

33 hasil untuk "Bastholt, Lars"

Menampilkan 1–20 · 0,58 detik · RSS

  1. Artikel Jurnal Teks lengkap

    The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients

    Frary, Evan C.; Gad, Dorte; Bastholt, Lars dkk.

    EJNMMI Res · 2016 · Inggris · PubMed Central

    BACKGROUND: On April 1, 2015, Odense University Hospital (OUH) began a new diagnostic strategy, wherein all malignant melanoma (MM) patients in the Region of Southern Denmark with a positive sentinel lymph node biopsy (SLNB) underwent FDG-PET/CT preoperatively prior to lymph node dissection (LND)…

  2. Artikel Jurnal Teks lengkap

    A Placebo-Controlled, Blinded and Randomised Study on the Effects of Recombinant Human Thyrotropin on Quality of Life in the Treatment of Thyroid Cancer

    Nygaard, Birte; Bastholt, Lars; Bennedbæk, Finn Noe dkk.

    Eur Thyroid J · 2013 · Inggris · PubMed Central

    BACKGROUND: It is well known that thyroid hormone withdrawal (THW) in thyroid cancer patients can induce a decrease in quality of life (QOL). Recombinant human thyrotropin (rh-TSH) has been used to avoid this; however, no blinded studies have ever documented the effect. OBJECTIVE: To compare QOL in…

  3. Artikel Jurnal Teks lengkap

    Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial

    Tolstrup, Lærke K.; Pappot, Helle; Bastholt, Lars dkk.

    J Patient Rep Outcomes · 2022 · Inggris · PubMed Central

    INTRODUCTION: In a randomized controlled trial, we previously investigated if melanoma patients receiving checkpoint inhibitors had fewer severe immune-related adverse events (irAEs) when they reported symptoms using electronic patient-reported outcomes (ePRO) with triggered alerts as an add-on to…

  4. Artikel Jurnal Teks lengkap

    Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy

    Tolstrup, Lærke K.; Bastholt, Lars; Zwisler, Ann-Dorthe dkk.

    J Patient Rep Outcomes · 2019 · Inggris · PubMed Central

    CONTEXT: Toxicity-monitoring plays an important role in all cancer treatment, however, early recognition is vital for detecting and treating immune-related symptoms. Preparing a Patient Reported Outcomes tool and including melanoma patients receiving immunotherapy in the reporting of symptoms, may…

  5. Artikel Jurnal Teks lengkap

    Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients’ and Clinicians’ Experiences

    Tolstrup, Lærke K; Pappot, Helle; Bastholt, Lars dkk.

    J Med Internet Res · 2020 · Inggris · PubMed Central

    BACKGROUND: The benefits of electronic patient reported outcomes (PRO) questionnaires have been demonstrated in many settings, including in hospitals and patient homes. However, it remains to be investigated how melanoma patients and their treating clinicians experience the electronic…

  6. Artikel Jurnal Teks lengkap

    Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma

    Soerensen, Anne Vest; Ellebaek, Eva; Bastholt, Lars dkk.

    Cancers (Basel) · 2020 · Inggris · PubMed Central

    SIMPLE SUMMARY: New cancer treatments have prolonged the lives for patients with metastatic melanoma in clinical trials. However, patients in clinical trials often presents with a better prognosis than other patients. It is therefore important to examine the effect of the new treatments in a…

  7. Artikel Jurnal Teks lengkap

    Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma

    Køstner, Anne Helene; Ellegaard, Mai-Britt Bjørklund; Christensen, Ib Jarle dkk.

    Cancer Immunol Immunother · 2014 · Inggris · PubMed Central

    Fever is frequently observed in conjunction with interleukin-2 (IL-2)-based immunotherapy. Traditionally, fever has been regarded as an undesirable side effect and treated with fever-lowering drugs. However, new insights in tumor immunology suggest that elevated temperature may facilitate a more…

  8. Artikel Jurnal Teks lengkap

    Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form

    Tolstrup, Lærke K.; Pappot, Helle; Zangger, Graziella dkk.

    Health Qual Life Outcomes · 2018 · Inggris · PubMed Central

    AIM: No suitable Danish questionnaire exists to evaluate patient satisfaction with various patient reported outcome measures. Thus, the aim of this research project was to conduct a study on the translation and cultural adaption of an American patient reported experience measures questionnaire…

  9. Artikel Jurnal Teks lengkap

    Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

    Kverneland, Anders H.; Enevold, Christian; Donia, Marco dkk.

    Oncoimmunology · 2018 · Inggris · PubMed Central

    Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers. Development of anti-drug antibodies (ADAs) after treatment with other biopharmaceuticals has been thoroughly described, but the induction of ADAs…

  10. Artikel Jurnal Teks lengkap

    The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial

    Tolstrup, Lærke K.; Bastholt, Lars; Dieperink, Karin B. dkk.

    J Patient Rep Outcomes · 2020 · Inggris · PubMed Central

    BACKGROUND: A randomized controlled pilot trial was conducted to assess if melanoma patients treated with immunotherapy had the number of grade 3 or 4 adverse events during treatment reduced by 50% using a tailored electronic patient-reported outcomes tool in addition to standard toxicity…

  11. Artikel Jurnal Teks lengkap

    Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

    Oddershede, Jonas K.; Meklenborg, Ida K.; Bastholt, Lars dkk.

    Acta Oncol · 2025 · Inggris · PubMed Central

    BACKGROUND: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF). This study aimed to evaluate the incidence, timeline, risk factors, and…

  12. Artikel Jurnal Teks lengkap

    Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid Tissue

    Folkestad, Lars; Brandt, Frans; Brix, Thomas dkk.

    Eur Thyroid J · 2017 · Inggris · PubMed Central

    BACKGROUND: Graves disease (GD) is an autoimmune condition characterized by the presence of antibodies against the thyrotropin receptor (TRAB), which stimulate the thyroid gland to produce excess thyroid hormone. Theoretically, TRAB could stimulate highly differentiated thyroid cancer tissue and/or…

  13. Artikel Jurnal Teks lengkap

    Large Discrepancy in the Results of Sensitive Measurements of Thyroglobulin Antibodies in the Follow-Up on Thyroid Cancer: A Diagnostic Dilemma

    Nygaard, Birte; Bentzen, Jens; Laurberg, Peter dkk.

    Eur Thyroid J · 2012 · Inggris · PubMed Central

    During follow-up on patients treated for differentiated thyroid cancer, thyroglobulin (Tg) antibodies can interfere with the Tg assay, making the use of Tg less reliable as a tumor marker. PURPOSE: To compare Tg and Tg autoantibodies (Tg-Ab) methods used in Denmark, regarding the number of patient…

  14. Artikel Jurnal Teks lengkap

    Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab

    Noringriis, Inge Mansfield; Donia, Marco; Madsen, Kasper dkk.

    Br J Cancer · 2025 · Inggris · PubMed Central

    BACKGROUND: A substantial number of patients with metastatic melanoma (MM) treated with anti-PD-1 monotherapy have initial stable disease (SD), yet the real-world prognosis of these patients remains unclear. METHODS: In this nationwide cohort study, we analysed real-world outcomes of patients with…

  15. Artikel Jurnal Teks lengkap

    Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial

    Prasmickaite, Lina; Berge, Gisle; Bettum, Ingrid J. dkk.

    Cancer Immunol Immunother · 2015 · Inggris · PubMed Central

    Malignant melanoma is highly aggressive cancer with poor prognosis and few therapeutic options. Interferon alpha (IFN-α) has been tested as adjuvant immunotherapy in high-risk melanoma patients in a number of studies, but its beneficial role is controversial. Although IFN-α treatment can prolong…

  16. Artikel Jurnal Teks lengkap

    Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

    Iversen, Trine Zeeberg; Brimnes, Marie Klinge; Nikolajsen, Kirsten dkk.

    Oncoimmunology · 2013 · Inggris · PubMed Central

    Therapeutic strategies to deplete lymphocytes, especially regulatory T cells, in cancer patients have been proposed to increase the benefits of (immuno)chemotherapy. In this study, we explored the influence of temozolomide (TMZ) on different T-cell populations and addressed if the depletion of…

  17. Artikel Jurnal Teks lengkap

    Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels

    Vihinen, Pia; Tervahartiala, Taina; Sorsa, Timo dkk.

    Cancer Immunol Immunother · 2014 · Inggris · PubMed Central

    Matrix metalloproteinases (MMPs) are important enzymes in tissue turnover and various inflammatory processes. In this study, it was evaluated whether serum MMP-8 can predict the response to adjuvant interferon alfa-2b (IFN-α) therapy in patients with operated high-risk cutaneous melanoma…

  18. Artikel Jurnal Teks lengkap

    Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

    Kirkwood, John M.; Bastholt, Lars; Robert, Caroline dkk.

    Clin Cancer Res · 2011 · Inggris · PubMed Central

    PURPOSE: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. EXPERIMENTAL DESIGN: This phase II…

  19. Artikel Jurnal Teks lengkap

    Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial

    Kreissl, Michael C.; Bastholt, Lars; Elisei, Rossella dkk.

    J Clin Oncol · 2020 · Inggris · PubMed Central

    PURPOSE: We conducted a post hoc analysis of the vandetanib phase III trial involving patients with advanced medullary thyroid cancer (MTC) to assess the efficacy and safety of vandetanib in patients with progressive and symptomatic MTC. The primary objective of the analysis was to determine…

  20. Artikel Jurnal Teks lengkap

    Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer

    Bastholt, Lars; Kreissl, Michael C.; Führer, Dagmar dkk.

    Eur Thyroid J · 2016 · Inggris · PubMed Central

    OBJECTIVES: Effective management of adverse events (AEs) following vandetanib treatment is important to maximize clinical benefits. We examined whether more frequent contact with vandetanib-treated patients reduced AEs of CTCAE grade 2 or higher. STUDY DESIGN: In this open-label, multicentre, phase…